Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR4 | P46093 | 7/20 | 0.33 |
| ▸ | CTSK | P43235 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | RAD52 | P43351 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30299362 | 1.00 | GPR4 (0.33) | GPR4CTSKKDM4ERAD52L3MBTL1 | |
| SCHEMBL30299376 | 0.92 | GPR4 (0.38) | GPR4CTSK | |
| SCHEMBL30299399 | 0.90 | GPR4 (0.37) | GPR4CTSKKDM4ERAD52L3MBTL1 | |
| SCHEMBL30299380 | 0.84 | PRKCQ (0.31) | — | |
| SCHEMBL30299279 | 0.82 | LTA4H (0.36) | MAPT | |
| SCHEMBL30299348 | 0.81 | GPR4 (0.42) | GPR4CTSKKDM4E | |
| SCHEMBL30299385 | 0.80 | KCNH2 (0.37) | — | |
| SCHEMBL30299358 | 0.80 | GPR4 (0.43) | GPR4CTSKL3MBTL1 | |
| SCHEMBL30299386 | 0.79 | SIGMAR1 (0.40) | KDM4EMAPT | |
| SCHEMBL30299374 | 0.79 | SMN1; SMN2 (0.35) | GPR4CTSKKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080182862-A1 | N3-HETEROARYL SUBSTITUTED TRIAZOLES AND N5-HETEROARYL SUBSTITUTED TRIAZOLES USEFUL AS AXL INHIBITORS | RIGEL PHARMACEUTICALS, INC. (US) | 2008-07-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080182862-A1 | N3-HETEROARYL SUBSTITUTED TRIAZOLES AND N5-HETEROARYL SUBSTITUTED TRIAZOLES USEFUL AS AXL INHIBITORS | AXL, TYRO3, ERBB3 | GPR4 979/4885CTSK 1697/4885KDM4E 4225/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.